A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERS

The present disclosure relates to the treatment of metabolic disorders, such as metabolic syndrome, obesity, and type 2 diabetes. Adjunct therapies and combination therapies that include a myostatin pathway inhibitor, used in conjunction with a GLP-1 pathway activator are disclosed. La présente inve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: CHAPRON, CHRISTOPHER, CHYUNG, YUNG, WEBSTER, MICAH T, LONG, KIMBERLY, FLIER, JEFFREY S, NOMIKOS, GEORGE
Format: Patent
Sprache:eng ; fre
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator CHAPRON, CHRISTOPHER
CHYUNG, YUNG
WEBSTER, MICAH T
LONG, KIMBERLY
FLIER, JEFFREY S
NOMIKOS, GEORGE
description The present disclosure relates to the treatment of metabolic disorders, such as metabolic syndrome, obesity, and type 2 diabetes. Adjunct therapies and combination therapies that include a myostatin pathway inhibitor, used in conjunction with a GLP-1 pathway activator are disclosed. La présente invention concerne le traitement de troubles métaboliques, tels que le syndrome métabolique, l'obésité et le diabète de type 2. L'invention concerne des polythérapies et des polythérapies qui comprennent un inhibiteur de la voie de passage de la myostatine, utilisé conjointement avec un activateur de la voie de passage du GLP-1.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3221555A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3221555A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3221555A13</originalsourceid><addsrcrecordid>eNqNjEEKgzAURN10Udre4V_AhYoH-MZoPphEkt-KKxFJV6UV7P1phNJ1F8MMzJs5JhuCHq1nZDLQI6sBRyCjqCK2LiYQVldkYm8NDMQKENquT7MfjYLphjvdRF293Ffs5H7ZgpaMle1IQE3eulo6f04O9_mxhcvXTwk0koVKw_qawrbOS3iG9ySwyPOsLEvMij-QD_vcN_g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERS</title><source>esp@cenet</source><creator>CHAPRON, CHRISTOPHER ; CHYUNG, YUNG ; WEBSTER, MICAH T ; LONG, KIMBERLY ; FLIER, JEFFREY S ; NOMIKOS, GEORGE</creator><creatorcontrib>CHAPRON, CHRISTOPHER ; CHYUNG, YUNG ; WEBSTER, MICAH T ; LONG, KIMBERLY ; FLIER, JEFFREY S ; NOMIKOS, GEORGE</creatorcontrib><description>The present disclosure relates to the treatment of metabolic disorders, such as metabolic syndrome, obesity, and type 2 diabetes. Adjunct therapies and combination therapies that include a myostatin pathway inhibitor, used in conjunction with a GLP-1 pathway activator are disclosed. La présente invention concerne le traitement de troubles métaboliques, tels que le syndrome métabolique, l'obésité et le diabète de type 2. L'invention concerne des polythérapies et des polythérapies qui comprennent un inhibiteur de la voie de passage de la myostatine, utilisé conjointement avec un activateur de la voie de passage du GLP-1.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20221229&amp;DB=EPODOC&amp;CC=CA&amp;NR=3221555A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,782,887,25571,76555</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20221229&amp;DB=EPODOC&amp;CC=CA&amp;NR=3221555A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CHAPRON, CHRISTOPHER</creatorcontrib><creatorcontrib>CHYUNG, YUNG</creatorcontrib><creatorcontrib>WEBSTER, MICAH T</creatorcontrib><creatorcontrib>LONG, KIMBERLY</creatorcontrib><creatorcontrib>FLIER, JEFFREY S</creatorcontrib><creatorcontrib>NOMIKOS, GEORGE</creatorcontrib><title>A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERS</title><description>The present disclosure relates to the treatment of metabolic disorders, such as metabolic syndrome, obesity, and type 2 diabetes. Adjunct therapies and combination therapies that include a myostatin pathway inhibitor, used in conjunction with a GLP-1 pathway activator are disclosed. La présente invention concerne le traitement de troubles métaboliques, tels que le syndrome métabolique, l'obésité et le diabète de type 2. L'invention concerne des polythérapies et des polythérapies qui comprennent un inhibiteur de la voie de passage de la myostatine, utilisé conjointement avec un activateur de la voie de passage du GLP-1.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjEEKgzAURN10Udre4V_AhYoH-MZoPphEkt-KKxFJV6UV7P1phNJ1F8MMzJs5JhuCHq1nZDLQI6sBRyCjqCK2LiYQVldkYm8NDMQKENquT7MfjYLphjvdRF293Ffs5H7ZgpaMle1IQE3eulo6f04O9_mxhcvXTwk0koVKw_qawrbOS3iG9ySwyPOsLEvMij-QD_vcN_g</recordid><startdate>20221229</startdate><enddate>20221229</enddate><creator>CHAPRON, CHRISTOPHER</creator><creator>CHYUNG, YUNG</creator><creator>WEBSTER, MICAH T</creator><creator>LONG, KIMBERLY</creator><creator>FLIER, JEFFREY S</creator><creator>NOMIKOS, GEORGE</creator><scope>EVB</scope></search><sort><creationdate>20221229</creationdate><title>A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERS</title><author>CHAPRON, CHRISTOPHER ; CHYUNG, YUNG ; WEBSTER, MICAH T ; LONG, KIMBERLY ; FLIER, JEFFREY S ; NOMIKOS, GEORGE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3221555A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>CHAPRON, CHRISTOPHER</creatorcontrib><creatorcontrib>CHYUNG, YUNG</creatorcontrib><creatorcontrib>WEBSTER, MICAH T</creatorcontrib><creatorcontrib>LONG, KIMBERLY</creatorcontrib><creatorcontrib>FLIER, JEFFREY S</creatorcontrib><creatorcontrib>NOMIKOS, GEORGE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CHAPRON, CHRISTOPHER</au><au>CHYUNG, YUNG</au><au>WEBSTER, MICAH T</au><au>LONG, KIMBERLY</au><au>FLIER, JEFFREY S</au><au>NOMIKOS, GEORGE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERS</title><date>2022-12-29</date><risdate>2022</risdate><abstract>The present disclosure relates to the treatment of metabolic disorders, such as metabolic syndrome, obesity, and type 2 diabetes. Adjunct therapies and combination therapies that include a myostatin pathway inhibitor, used in conjunction with a GLP-1 pathway activator are disclosed. La présente invention concerne le traitement de troubles métaboliques, tels que le syndrome métabolique, l'obésité et le diabète de type 2. L'invention concerne des polythérapies et des polythérapies qui comprennent un inhibiteur de la voie de passage de la myostatine, utilisé conjointement avec un activateur de la voie de passage du GLP-1.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre
recordid cdi_epo_espacenet_CA3221555A1
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T09%3A57%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CHAPRON,%20CHRISTOPHER&rft.date=2022-12-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3221555A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true